Northern Trust Corp Increases Stock Position in Pharvaris (NASDAQ:PHVS)

Northern Trust Corp raised its position in Pharvaris (NASDAQ:PHVS - Free Report) by 483.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,932 shares of the company's stock after purchasing an additional 76,188 shares during the quarter. Northern Trust Corp owned 0.18% of Pharvaris worth $1,762,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Palumbo Wealth Management LLC acquired a new position in shares of Pharvaris in the fourth quarter valued at approximately $196,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Pharvaris in the fourth quarter valued at about $111,000. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares during the period. Geode Capital Management LLC increased its holdings in Pharvaris by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after purchasing an additional 1,356 shares in the last quarter. Finally, FMR LLC increased its holdings in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after purchasing an additional 189,714 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently issued reports on PHVS. Cantor Fitzgerald cut their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. JMP Securities boosted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.

Pharvaris Price Performance

Shares of PHVS stock traded down $0.19 during trading hours on Friday, hitting $16.53. The stock had a trading volume of 189,848 shares, compared to its average volume of 74,193. The stock's 50-day moving average price is $15.45 and its two-hundred day moving average price is $17.18. Pharvaris has a one year low of $11.51 and a one year high of $25.50. The stock has a market capitalization of $864.35 million, a price-to-earnings ratio of -5.90 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). As a group, equities research analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.